NASDAQ:IDRA - Idera Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.72 -0.28 (-9.33 %) (As of 03/22/2019 04:00 PM ET)Previous Close$2.72Today's Range$2.66 - $2.9852-Week Range$2.25 - $17.12Volume583,582 shsAverage Volume329,935 shsMarket Capitalization$75.13 millionP/E Ratio-1.19Dividend YieldN/ABeta2.57 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer. The company was founded in 1989 and is based in Exton, Pennsylvania. Receive IDRA News and Ratings via Email Sign-up to receive the latest news and ratings for IDRA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IDRA Previous Symbol CUSIPN/A CIK861838 Webwww.iderapharma.com Phone484-348-1600Debt Debt-to-Equity RatioN/A Current Ratio8.07 Quick Ratio8.07Price-To-Earnings Trailing P/E Ratio-1.19 Forward P/E Ratio-1.44 P/E GrowthN/A Sales & Book Value Annual Sales$660,000.00 Price / Sales113.83 Cash FlowN/A Price / Cash FlowN/A Book Value$2.35 per share Price / Book1.16Profitability EPS (Most Recent Fiscal Year)($2.28) Net Income$-59,880,000.00 Net Margins-9,045.47% Return on Equity-75.10% Return on Assets-65.61%Miscellaneous Employees36 Outstanding Shares27,620,000Market Cap$75.13 million Next Earnings Date5/8/2019 (Estimated) OptionableOptionable Idera Pharmaceuticals (NASDAQ:IDRA) Frequently Asked Questions What is Idera Pharmaceuticals' stock symbol? Idera Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDRA." When did Idera Pharmaceuticals' stock split? How did Idera Pharmaceuticals' stock split work? Shares of Idera Pharmaceuticals reverse split before market open on Monday, July 30th 2018. The 1-8 reverse split was announced on Friday, July 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 27th 2018. An investor that had 100 shares of Idera Pharmaceuticals stock prior to the reverse split would have 13 shares after the split. How were Idera Pharmaceuticals' earnings last quarter? Idera Pharmaceuticals Inc (NASDAQ:IDRA) announced its quarterly earnings results on Wednesday, March, 6th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.51) by $0.06. The biotechnology company had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.12 million. Idera Pharmaceuticals had a negative return on equity of 75.10% and a negative net margin of 9,045.47%. View Idera Pharmaceuticals' Earnings History. When is Idera Pharmaceuticals' next earnings date? Idera Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for Idera Pharmaceuticals. What price target have analysts set for IDRA? 6 brokerages have issued 12 month target prices for Idera Pharmaceuticals' shares. Their predictions range from $7.00 to $32.00. On average, they anticipate Idera Pharmaceuticals' share price to reach $19.00 in the next year. This suggests a possible upside of 598.5% from the stock's current price. View Analyst Price Targets for Idera Pharmaceuticals. What is the consensus analysts' recommendation for Idera Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Idera Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Idera Pharmaceuticals. Has Idera Pharmaceuticals been receiving favorable news coverage? News stories about IDRA stock have trended somewhat negative on Saturday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Idera Pharmaceuticals earned a daily sentiment score of -1.9 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the company's share price in the near future. Are investors shorting Idera Pharmaceuticals? Idera Pharmaceuticals saw a increase in short interest in the month of February. As of February 28th, there was short interest totalling 1,226,617 shares, an increase of 48.6% from the February 15th total of 825,286 shares. Based on an average trading volume of 372,302 shares, the days-to-cover ratio is currently 3.3 days. Currently, 5.5% of the shares of the company are short sold. View Idera Pharmaceuticals' Current Options Chain. Who are some of Idera Pharmaceuticals' key competitors? Some companies that are related to Idera Pharmaceuticals include Cellular Biomedicine Group (CBMG), CASI Pharmaceuticals (CASI), Gamida Cell (GMDA), Novavax (NVAX), Eiger Biopharmaceuticals (EIGR), Harpoon Therapeutics (HARP), Sutro Biopharma (STRO), LogicBio Therapeutics (LOGC), Jounce Therapeutics (JNCE), La Jolla Pharmaceutical (LJPC), Compugen (CGEN), ADMA Biologics (ADMA), Neon Therapeutics (NTGN), Erytech Pharma (ERYP) and Allena Pharmaceuticals (ALNA). What other stocks do shareholders of Idera Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Idera Pharmaceuticals investors own include Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Inovio Pharmaceuticals (INO), Verastem (VSTM), Anavex Life Sciences (AVXL), Celldex Therapeutics (CLDX), Zynerba Pharmaceuticals (ZYNE), Dynavax Technologies (DVAX), Progenics Pharmaceuticals (PGNX) and Rigel Pharmaceuticals (RIGL). Who are Idera Pharmaceuticals' key executives? Idera Pharmaceuticals' management team includes the folowing people: Mr. Vincent J. Milano, Pres, CEO & Director (Age 55)Mr. John J. Kirby, VP of Fin., Principal Financial Officer & Principal Accounting Officer (Age 47)Dr. Jonathan Yingling, Sr. VP of Early Devel. & Chief Scientific Officer (Age 50)Mr. Robert Clayton Fletcher, Sr. VP of Bus. Devel. & Strategic Planning (Age 56)Dr. Joanna C. Horobin, Sr. VP & Chief Medical Officer (Age 64) Who are Idera Pharmaceuticals' major shareholders? Idera Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.44%), Millennium Management LLC (2.22%), Broadfin Capital LLC (1.79%), Assenagon Asset Management S.A. (1.53%), Candriam Luxembourg S.C.A. (1.07%) and Geode Capital Management LLC (0.85%). Company insiders that own Idera Pharmaceuticals stock include Bros Advisors Lp Baker, Bryant David Lim, Carol Schafer, Invest Corp Pillar, James A Geraghty, Joanna Horobin and Vincent Milano. View Institutional Ownership Trends for Idera Pharmaceuticals. Which major investors are selling Idera Pharmaceuticals stock? IDRA stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC. View Insider Buying and Selling for Idera Pharmaceuticals. Which major investors are buying Idera Pharmaceuticals stock? IDRA stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Zacks Investment Management, Millennium Management LLC, Two Sigma Investments LP, Candriam Luxembourg S.C.A., Rhumbline Advisers, Dimensional Fund Advisors LP and Dimensional Fund Advisors LP. Company insiders that have bought Idera Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Bryant David Lim, Carol Schafer, James A Geraghty, Joanna Horobin and Vincent Milano. View Insider Buying and Selling for Idera Pharmaceuticals. How do I buy shares of Idera Pharmaceuticals? Shares of IDRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Idera Pharmaceuticals' stock price today? One share of IDRA stock can currently be purchased for approximately $2.72. How big of a company is Idera Pharmaceuticals? Idera Pharmaceuticals has a market capitalization of $75.13 million and generates $660,000.00 in revenue each year. The biotechnology company earns $-59,880,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. Idera Pharmaceuticals employs 36 workers across the globe. What is Idera Pharmaceuticals' official website? The official website for Idera Pharmaceuticals is http://www.iderapharma.com. How can I contact Idera Pharmaceuticals? Idera Pharmaceuticals' mailing address is 505 EAGLEVIEW BLVD. SUITE 212, EXTON PA, 19341. The biotechnology company can be reached via phone at 484-348-1600 or via email at [email protected] MarketBeat Community Rating for Idera Pharmaceuticals (NASDAQ IDRA)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 299 (Vote Outperform)Underperform Votes: 204 (Vote Underperform)Total Votes: 503MarketBeat's community ratings are surveys of what our community members think about Idera Pharmaceuticals and other stocks. Vote "Outperform" if you believe IDRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDRA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/23/2019 by MarketBeat.com StaffFeatured Article: What is a front-end load?